CLL treatment sequence study for patients in GCLLSG trials
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have given signed permission to take part (informed consent).
- You must have a confirmed diagnosis of CLL when you started your first treatment in a GCLLSG study.
- Your first treatment was in one of these studies: CLL13, CLL14, or CLL17.
- Any later treatments were recorded in your first study or you agreed to have them recorded in this observational trial.
- You are willing and able to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and bendamustine) as a first treatment for people with chronic lymphocytic leukemia (CLL) who have not had any previous therapy. The goal is to see if this combination is safe and effective.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.